Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patients aged from18- 60 years.~2. Chronic HCV infection with Plasma HCV RNA greater than 15,000 IU/mL~3. Treatment naïve.~4. compensated liver cirrhosis.~5. Absence of coinfection with HBV or HIV.~Exclusion Criteria:~1. Patients with hepatitis B virus or HIV.~2. prior antiviral therapy.~3. Haemoglobin level less than 10mg/dl.~4. Decompensated liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily (Type: OTHER): Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if \< 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week

Based on this trial design, predict the completion outcome and termination type (if applicable).